Overview

Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy

Status:
Completed

Trial end date:
2005-12-01

Target enrollment:

Participant gender:

Summary

To assess the change in hemoglobin levels when iron sucrose was added to a regimen of weekly, fixed doses of erythropoietin in patients who had or had not responded to erythropoietin therapy alone.

Phase:

Phase 3

Details

Lead Sponsor:

American Regent, Inc.
Luitpold Pharmaceuticals

Treatments:

Epoetin Alfa
Ferric Oxide, Saccharated
Iron